Hemolytic-uremic syndrome epidemiology and demographics

	Hemolytic-uremic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemolytic-uremic syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemolytic-uremic syndrome epidemiology and demographics
CDC on Hemolytic-uremic syndrome epidemiology and demographics
Hemolytic-uremic syndrome epidemiology and demographics in the news
Blogs on Hemolytic-uremic syndrome epidemiology and demographics
Directions to Hospitals Treating Hemolytic-uremic syndrome
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.^[1]
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Patients of all age groups may develop [disease name].
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
[Chronic disease name] is usually first diagnosed among [age group].
[Acute disease name] commonly affects [age group].

There is no racial predilection to [disease name].
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

[Disease name] affects men and women equally.
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

↑ Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.